In a new letter sent to MedImmune Inc. (MEDI), 0.75% shareholder Matrix Asset Advisors reiterated their view that it would be in the best interest of shareholders to sell the company. The firm also expressed this view in a November 21st letter to the company.
The firm believes that while the Company has amassed an array of world class products and intellectual property, the best way to realize the intrinsic value of the assets is by selling the company to a motivated strategic buyer.
While the firm didn't name names, they believe that several major pharmaceutical companies would be highly motivated to acquire the company. The firm also notes that industry analysts see a takeover value in the range of $40-$45 per share.
MEDI 1-yr chart: